Very sensible post. Something along the lines of an HGSI Glaxo Smith Klein deal regarding Benlysta. A 50/50 development and cost /profit share structure. With a large cash upfront deal. Very likely scenario in my book. Might not be today or tomorrow, but after a larger clinical trial progresses. Will all depend on future results in trial. Nothing more. Nothing less.
I think the Mayo results are substantial enough to justify an agreement in the near future, with most of the cash of any such agreement coming on the backside. Geron may have to give a little more than they would like to get this done, but I believe they will do this sooner rather than later. The only other option is a buyout, and they do not have the data to support this option for what it might be worth.